INTRODUCTION
============

Emerging knowledge about the association of the variant alleles of different genes with the human diseases has focused attention on the development of technologies to rapidly discriminate between different genotypes ([@b1]). New methods are important, both to facilitate the acquisition of genotyping data and to better translate this knowledge into diagnostic and therapeutic applications. Studies of the genetics of host immunity, for example, are revealing novel pathogenic mechanisms that are important for understanding infectious diseases as they affect different human populations ([@b2],[@b3]). Rapid and low-cost genotyping methods are especially important for studies in the developing world, where the facilities for DNA analysis are limited and where the timely, on-site utilization of genetic information could make an impact on morbidity and mortality.

Our studies of polymorphisms in the gene for the cytokine, macrophage migration inhibitory factor (MIF), and its role in malaria infection has prompted us to develop a robust genotyping method that can be performed on-site, in rural field settings, and at low-cost and turnaround time. MIF plays an important role in the innate and the adaptive immune response, and it is encoded by a functionally polymorphic gene that has been linked to the incidence or the severity of different inflammatory conditions ([@b4],[@b5]). These *MIF* alleles differ in the structure of their promoter region, which varies by the presence of a tetranucleotide, CATT, that is repeated between 5 and 8 times in the promoter (−794 CATT~5--8~) ([@b6]). This repeat regulates basal and stimulus-induced transcriptional activity, which increases almost proportionally with repeat number in defined *in vitro* assay systems. A single nucleotide polymorphism (SNP) (−173 G/C) in the *MIF* promoter may also influence promoter activity, either by linkage disequilibrium or by an interaction with the tetranucleotide site ([@b7]--[@b9]).

The close interplay between the genes of the immune system and the host response to infection has led us to investigate the distribution of variant *MIF* alleles in populations, in which different infectious diseases are endemic, with the aim of better understanding the role of selective pressures on the evolution of the *MIF* locus. Toward this end, we have developed and implemented a thin-film optical biosensor chip for genotyping of both tetranucleotide CATT repeats and SNPs in a single analysis that greatly facilitates the examination of small quantities of DNA obtained in the field. These chips are based on an allele-discriminating oligonucleotide array that provides a direct visual readout of the different *MIF* promoter polymorphisms. We document, herein, the application of this technology to the analysis of *MIF* gene polymorphisms in dried blood spots collected in a rural hospital where malaria is endemic.

METHODS
=======

Patient samples
---------------

DNA specimens from normal controls of known *MIF* genotype were used to develop the biosensor methodology. Validation was performed on a random selection of DNA specimens culled from ongoing studies of *MIF* genotype, and included Caucasians, African-Americans, North East Asians (Koreans) and the African sub-groups described in the text. The African sub-group specimens were collected either by K. K. Kidd and J. R. Kidd, or by one of their collaborators as part of their long-term studies on human genetic diversity. The malaria-infected samples were obtained as part of investigations at the Macha Mission Hospital in Choma, Zambia, which is holoendemic for *Plasmodium falciparum* malaria. These specimens consisted of blood samples that had been spotted on filter paper, dried and stored for several months. Parasitemia was assessed on hospital admission by enumeration of infected red cells in thick blood smears. All samples were obtained and utilized in accordance with institutional and local IRB protocols. The SAS statistical software package was used to perform χ^2^ analysis and logistic regression to determine the relationship between parasitemia and *MIF* genotype.

DNA extraction
--------------

Genomic DNA was isolated from patient blood or from the blood spots dried on filter papers using the QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA) and the recommended protocols provided by the manufacturer.

DNA amplification by multiple displacement amplification
--------------------------------------------------------

DNA extracted from blood spots dried on filter papers was amplified by multiple displacement amplification (MDA) ([@b10]). The MDA reactions were performed overnight at 31°C in 50 μl of reaction solution containing 37.5 mM Tris--HCl (pH 7.5), 50 mM KCl, 10 mM MgCl~2~, 5 mM (NH~4~)~2~SO~4~, 1 mM dNTP, 0.05 mM thiophosphate-modified random hexamer (5′-NNNN^s^N^s^N), 1--5 ng genomic DNA, 0.2 U yeast pyrophosphatase and 1 U Phi29 polymerase. The products of the MDA reaction were resolved on a 1% agarose gel stained with ethidium bromide. The yield of amplified genomic DNA was between 15 and 20 μg in a 50 μl reaction solution.

MIF DNA fragment amplification by PCR
-------------------------------------

Oligonucleotide primer sets were designed to amplify regions within the *MIF* promoter that corresponded to DNA product sizes of 119, 123, 127 and 131 bp for the 5-, 6-, 7- and 8-CATT repeat polymorphisms, respectively ([Table 1](#tbl1){ref-type="table"}). An additional set of primers was used for the −173 G/C SNP and produced a PCR product size of 129 bp. The PCRs were carried out in a 50 μl solution containing 1× PCR buffer (AmpliTaq Gold; Applied Biosystem), 2.5 mM MgCl~2~, 0.2 mM dNTP, 10 pmol of each forward and reverse primers, 100 ng of genomic DNA or MDA-amplified genomic DNA and 1 U AmpliTaq Gold DNA polymerase. For the CATT repeat, the PCR program was as follows: 95°C for 10 min, followed by 40 cycles at 94°C for 30 s, 56°C for 30 s, 72°C for 1 min and final extension at 72°C for 10 min, and for the −173 SNP, the PCR program was 95°C for 10 min, followed by 40 cycles of 94°C for 30 s, 62°C for 30 s, 72°C for 1 min and final extension at 72°C for 10 min.

Oligonucleotide probe synthesis
-------------------------------

The oligonucleotide probes were designed based on the general approach described previously ([@b11]), and with the detailed sequence information provided in [Table 1](#tbl1){ref-type="table"}. For the CATT repeat, the 4 P1 capture probes have 5′-aldehyde groups, 10 deoxyadenosine residues at their 5′ ends and 30 bases of upstream sequence, followed by a different number (from 1 to 4) of the CATT repeat, respectively. The P2 detection probe contains 4 copies of CATT and 20 bases of downstream sequence, with a biotin at its 3′ end for detection and a phosphate group at its 5′ end for ligation. The P1 and P2 probes were synthesized by the Yale Keck Biotechnology Facility at 40/50 nmol scale and were used without post-synthesis purification. Four complementary, single-stranded artificial targets with 5--8 copies of the AATG repeat flanked by 30 bases of the *MIF* promoter sequences both upstream and downstream of the repeat motif also were synthesized.

Detection of *MIF* CATT repeat polymorphism and −173 G/C SNP on thin-film biosensor chips
-----------------------------------------------------------------------------------------

The *MIF* CATT repeat polymorphism and the −173 G/C SNP detection are performed by modifying solid-phase techniques described previously ([@b11]). The P1 capture probes are manually spotted in a format shown in [Figure 1B](#fig1){ref-type="fig"} on hydrazine-functionalized, thin-film biosensor chips (Thermo Electron, Louisville, CO) using 0.3 μl of 1 μM P1 in 0.1 M phosphate buffer, pH 7.8 and 10% glycerol. After incubation for 2 h at room temperature in a humid chamber, the chips are washed with 0.1% SDS at 60°C for 30 min, rinsed with water and dried. A ligation mixture containing 20 mM Tris--HCl, pH 8.3, 25 mM KCl, 10 mM MgCl~2~, 0.5 mM NAD, 0.01% Triton X-100, 5 mg/ml acid-treated casein, 10% formamide and 0.04 U/μl mutant Ampligase (Lys294Arg of *Thermus thermophilus* ligase) is applied to each chip and prewarmed to 60°C. The synthetic targets or *MIF* PCR amplicons from patient samples at a concentration of 100 fmol in 10 μl water are denatured at 95°C for 3 min in the presence of 100 fmol of the P2-biotin probe. After denaturation, 10 μl of this solution is immediately added to the pre-incubated ligation mixture and incubated at 60°C for 20 min. A stringent wash with 0.01 M NaOH at 60°C is applied three times, and this is followed by briefly rinsing three times with 0.1× standard saline citrate (SSC) at room temperature. The chips are then incubated at room temperature for 10 min with 100 μl of an anti-biotin--IgG--horseradish peroxidase conjugate (Jackson ImmunoResearch Lab; 1:1000 dilution from a 1 mg/ml stock in a buffer containing 5× SSC and 5 mg/ml acid-treated casein). After briefly washing three times with 0.1× SSC, 100 μl of a tetramethyl benzidine formulation from BioFX Lab is added to the chips and incubated for 5 min at room temperature, then rinsed with ddH~2~O and air dried. The CATT and SNP polymorphisms are scored visually and the results are recorded by imaging under a dissection microscope fitted with a digital camera.

RESULTS AND DISCUSSION
======================

[Figure 1](#fig1){ref-type="fig"} illustrates the hybridization and ligation-based detection strategy of the biosensor methodology used for detecting the MIF promoter CATT repeat, which is present in a copy number of 5--8, and the −173 G/C SNP. Of importance, prior ligation-based assays have been found to be efficient only for discriminating polymorphic alleles of short microsatellite repeats \<30 bases ([@b11],[@b12]). Ligation of longer repeats lacks specificity because of the looping out of repeat units in the probe/target hybrids. The loopout often occurs in an area outside of the ligase footprint that can span 26--30 bases ([@b12]). To avoid the formation of loopouts in the *MIF* CATT repeat sequence, we divided the repeat into the capture probes 'P1', with CATT 1, 2, 3 or 4, and 'P2', with CATT4 ([Figure 1A](#fig1){ref-type="fig"}), thereby ensuring that the ligase footprint covers 6--7-CATT repeat units. Four capture probes with 1, 2, 3 and 4 CATT repeat units, respectively, together with 30 bases of the upstream adjacent unique MIF sequence (see detailed sequences in [Table 1](#tbl1){ref-type="table"}) are covalently arrayed by the reaction between an aldehyde group at their 5′-termini and the hydrazine group on the chip surface. A detection probe, P2, with 4 copies of the CATT unit and 20 bases of the downstream adjacent and unique MIF sequence carries a biotin at the 3′ end for detection and a phosphate at its 5′ end for ligation. When target DNA with a variable number of the CATT unit (from 5 to 8, e.g. the 6-CATT shown in [Figure 1A](#fig1){ref-type="fig"}), is hybridized with the P1 and P2 probes on the chip surface in the presence of a thermostable DNA ligase, the enzyme selects only perfectly matched P1+P2/target for ligation. This reaction results in the immobilization of the biotinylated P2 probe at the matched P1 probe position on the chip surface. After a stringent wash to remove all non-ligated molecules, a biotin-associated detection procedure is applied to generate a color that can be visualized by the unaided human eye. The biochips can also be printed by high-throughput 'spotting' of the requisite capture probes onto hydrazine-functionalized thin-film biosensor chips. The entire methodology is low in cost and once printed, the chips are robust and require no instrumentation for analysis.

Using single-strand synthetic targets with tetranucleotide repeats of 5, 6, 7 or 8 AATG, we first tested the detection specificity for the different *MIF* CATT repeat sequences. A modified ligation condition with 10% formamide in the standard ligation mixture ([@b11]) gave unambiguous discrimination of the CATT repeat copy number. The allele-specific ligation strategy was also used for the simultaneous detection of the MIF SNP G/C −173.

To test for the accuracy of genotyping the CATT repeat polymorphism and the −173 SNP simultaneously by the biosensor chip, we analyzed an initial 30 genomic DNA samples that had been previously studied for *MIF* genotype. In our standard methodology, the CATT repeat polymorphism is detected by capillary electrophoresis of PCR products amplified to span the tetranucleotide region, and the −173 G/C SNP is determined by the ddNTP primer extension method and capillary electrophoresis, or by pyrosequencing ([@b6]). The typings of the CATT repeat and −173 SNP obtained by using the biosensor methodology were compared initially in a blinded fashion. Representative images are shown in [Figure 1C](#fig1){ref-type="fig"} and the optical biosensor genotypes are listed in [Table 2](#tbl2){ref-type="table"}. There was complete concordance of the −173 G/C SNP genotypes between the two methods. We observed one discrepancy for a previously analyzed DNA sample bearing the 8-CATT repeat. The initial chromatographic analysis for sample 1418 showed that one PCR product peak eluted in an intermediate position for that expected is either the 7-CATT or the 8-CATT repeat. The peak was scored as '8-CATT' by the capillary electrophoresis (5/8), but 7-CATT by the biosensor chip (5/7). Subsequent reanalysis of this DNA sample by capillary electrophoresis verified the presence of 7-CATT and the scoring of this sample as '5/7'. The concordance with typing data for the −173 G/C SNP and the ability to identify errors in the CATT repeat obtained by capillary electrophoresis indicate that genotyping by optical biosensor chips is highly accurate.

As one phase of an ongoing project to study the association between *MIF* polymorphisms and severe malarial disease, we plan to genotype several hundred DNA specimens obtained in rural field settings. Finger stick blood samples are routinely collected and dried onto filter papers at local hospitals and stored on-site under ambient conditions. Limited amounts of genomic DNA are present in these blood-spotted filter papers, and a pre-amplification step, typically by MDA technology ([@b10]), allows these precious samples to be used for hundreds of PCRs. To evaluate concordance between MDA products and unamplified genomic DNA for the ligation-based optical biosensor methodology, the 30 samples genotyped in the previous experiment were re-evaluated after MDA. Complete fidelity was observed between the unamplified genomic DNA and the MDA products for both the *MIF* CATT polymorphism and the −173 G/C SNP genotype. It is important to point out that with respect to the applicability of this method to other genes, some sequences may not be amenable to genotyping if they reside in repeated regions or are closely homologous to sequences found elsewhere in the genome, and additional optimization studies may be necessary.

The first 40 samples from patients in Zambia with *P.falciparum* malaria were collected and dried onto filter papers, stored at ambient temperature and the genomic DNA extracted with the QIAamp DNA Blood Mini kit (Qiagen). DNA yields were reliably 10--20 ng per sample. Ten nanograms of the isolated, genomic DNA was used for whole genome amplification by MDA in a standard 50 μl reaction, resulting in 15--20 μg of the MDA product per reaction. Targets for the *MIF* polymorphic genotyping were prepared by PCR of 100 ng of MDA-amplified products. The genotyping was performed on optical biosensor chips, and the genotypes and allele frequencies were compared with that of a previously reported Caucasian control group ([Table 3](#tbl3){ref-type="table"}). The initial data indicated a possible difference in the allelic distribution of *MIF* genotypes in different populations. In particular among the Zambian samples, there was a relative increase in the proportion of the low-expression 5-CATT allele, and a corresponding decrease in the proportion of the high-expression 6-CATT and 7-CATT alleles when compared with the recent studies in Caucasian populations ([@b6],[@b13]). Furthermore, the SNP analysis revealed a relative decrease in the −173G and a corresponding increase in the −173C in the Zambian samples when compared with previously studied Caucasian groups. We then analyzed small representative sets of DNA samples obtained from four different North African tribes and one African-American group. The allelic distribution, when summed over the different groups, appeared closer in distribution to the Zambian group than that described previously in Caucasian groups (included in [Table 3](#tbl3){ref-type="table"}) ([@b6],[@b13]).

With respect to clinical malaria infection, the small number of samples from Zambia did not permit us to make any meaningful determinations with respect to *MIF* alleles and disease complications or severity. Nevertheless, logistic regression analysis revealed that patients with the 5/X genotype (where X = 6-, 7- or 8-CATT allele) were significantly less likely to have parasitemia \>10 000 than those with an X/X genotype (*P* = 0.04) ([Table 4](#tbl4){ref-type="table"}). Whether this finding indeed signifies a protective effect of low-expression *MIF* alleles is yet to be confirmed by larger studies. Such an association could provide prognostic information and influence treatment options, which frequently necessitates blood transfusions that are costly and may carry risk of HIV or hepatitis infection.

The data suggesting ethnic variation in the allelic frequency of the functional *MIF* CATT promoter polymorphism prompted us to study additional samples, including a set of 100 control (disease-free) specimens obtained from Korea. This analysis showed an allelic distribution that was intermediate in 5-CATT (62%, 5/5 or 5/X) and non-5-CATT (38%, X/X) frequency when compared with the African or previously analyzed Caucasian groups ([@b6],[@b13]), and is in agreement with the proportions reported in a recent study of a Japanese population ([@b14]).

[Table 5](#tbl5){ref-type="table"} summarizes the data that we obtained for the frequency of the *MIF* alleles in different populations around the world. By a conservative test, none of the populations with sample size \>100 deviated significantly from Hardy--Weinberg ratios for the CATT polymorphism. Additional studies are necessary to determine if this distribution in CATT repeats reflect the relatedness between populations, as may be suggested by the representation in [Figure 2](#fig2){ref-type="fig"}. Ethnic variations in the distribution of different *MIF* alleles is an important finding, given the emerging association between these alleles and different inflammatory and infectious diseases ([@b5]--[@b9],[@b13],[@b14]). Racial or geographic variations in the population distribution of *MIF* alleles also suggest the possibility of different selective pressures acting on the *MIF* locus. Given the high prevalence of low-expression MIF alleles in Africa, these pressures could include historical exposure to tropical infections such as malaria, in which MIF is believed to play an important pathogenic role ([@b15]--[@b17]).

In conclusion, the robust optical biosensor methodology described herein has high fidelity when compared with the currently used methods and instrumentation, and it can be readily combined with the MDA technique to analyze minute quantities of DNA extracted from dried, whole blood specimens. This method will greatly facilitate the genotyping and population studies in different field settings, and it makes possible the rapid translation of genotyping information in the clinic into medical intervention.
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Figures and Tables
==================

![(**A**) Schematic representation for the detection of the *MIF* CATT tetranucleotide repeat by ligation of biotinylated detection probe P2 to a set of capture probes P1 with different copies of CATT repeat immobilized on thin-film biosensor chip surface in the presence of certain CATT target (i.e. CATT 6). (**B**) Array template for the detection of the 5-, 6-, 7- and 8-CATT repeats, and the −173 G/C SNP. Oligonucleotides are arrayed in duplicates, as shown. +: positive control, an aldehyde modified dA20-biotin probe. (**C**) Visual appearance of the biochip arrays of the representative *MIF* genotypes.](gni123f1){#fig1}

![Distribution of *MIF* CATT allele frequencies in different populations superimposed on human migration patterns.](gni123f2){#fig2}

###### 

Oligonucleotide sequences of capture probe P1, detection probe P2, synthetic targets and PCR primers

  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  CATT repeat                  
      Capture probe P1         P1-CATT-1 5′-CHO-AAAAAAAAAACTGCTATGTCATGGCTTATCTTCTTTCACCCATT
                               P1-CATT-2 5′-CHO-AAAAAAAAAACTGCTATGTCATGGCTTATCTTCTTTCACCCATTCATT
                               P1-CATT-3 5′-CHO-AAAAAAAAAACTGCTATGTCATGGCTTATCTTCTTTCACCCATTCATTCATT
                               P1-CATT-4 5′-CHO-AAAAAAAAAACTGCTATGTCATGGCTTATCTTCTTTCACCCATTCATTCATTCATT
      Detection probe P2       P2 biotin
                               5′-phosphate-CATTCATTCATTCATTCAGCAGTATTAGTCAATGTC-biotin-3′
      Synthetic target         Target AATG-5
                               GACATTGACTAATACTGCTG[AATGAATGAATGAATGAATG]{.ul}GGTGAAAGAAGATAAGCCATGACATAGCAG Target AATG-6
                               GACATTGACTAATACTGCTG[AATGAATGAATGAATGAATGAATG]{.ul}GGTGAAAGAAGATAAGCCATGACATAGCAG Target AATG-7
                               GACATTGACTAATACTGCTG[AATGAATGAATGAATGAATGAATGAATG]{.ul}GGTGAAAGAAGATAAGCCATGACATAGCAG Target AATG-8
                               GACATTGACTAATACTGCTG[AATGAATGAATGAATGAATGAATGAATGAATG]{.ul}GGTGAAAGAAGATAAGCCATGACATAGCAG
      PCR primer and product   Forward primer: CTATGTCATGGCTTATCTTC
                               Reverse primer: TCCACTAATGGTAAACTCGG
                               PCR products: 119, 123, 127 or 131
                               CTATGTCATGGCTTATCTTCTTTCACC**(CATT)5--8**CAGCAGTATTAGTCAATGTCTCTTGATATGCCTGGCACCTGCTAGATGGTCCCCGAGTTTACCATTAGTGGA
  SNP−173 G/C                  
      Capture probe P1         P1-G 5′-CHO-AAAAAAAAAACCGGAACAGGCCGATTTCTAGCCGCCAAGTGGAGAACAG**G**
                               P1-C 5′-CHO-AAAAAAAAAACCGGAACAGGCCGATTTCTAGCCGCCAAGTGGAGAACAG**C**
      Detection probe P2       P2 biotin
                               5′-phosphate-TTGGAGCGGTGCGCCGGGCTTA-biotin-3′
      Synthetic target         MIF−173 Target G AGCCCGGCGCACCGCTCCAA**C**CTGTTCTCCACTTGGCGGCTAGAAATCGGCCTGTTCCGG
                               MIF−173 Target CAGCCCGGCGCACCGCTCCAA**G**CTGTTCTCCACTTGGCGGCTAGAAATCGGCCTGTTCCGG
      PCR primer and product   MIF−173 Forward ACTAAGAAAGACCCGAGGCG
                               MIF−173 Reverse GCAGGACCCTGGGCGACT
                               PCR product 129 bp ACTAAGAAAGACCCGAGGCGAGGCCGGAACAGGCCGATTTCTAGCCGCCAAGTGGAGAACAG**G**TTGGAGCGGTGCGCCGGGCTTAGCGGCGGTTGCTGGAGGAACGGGCGGAGTCGCCCAGGGTCCTGC
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------

The underlined sequences designate the unique repeated sequences (5--8 repeats) present in the synthetic oligonucleotide target. The bolded residue designates the --173 G/C SNP.

###### 

Comparison of *MIF* genotypes of the CATT tetranucleotide repeat and the −173 G/C SNP in a selection of human DNA samples by optical biosensor chip and capillary electrophoresis

  Sample ID                              CATT repeat                               −173 G/C SNP                                    
  -------------------------------------- ----------------------------------------- ----------------------------------------- ----- -----
  0009                                   5/6                                       5/6                                       G/G   G/G
  0010                                   6/6                                       6/6                                       G/G   G/G
  0013                                   6/6                                       6/6                                       G/G   G/G
  0014                                   5/5                                       5/5                                       G/G   G/G
  0015                                   6/7                                       6/7                                       C/G   C/G
  0132                                   5/5                                       5/5                                       G/G   G/G
  0134                                   5/5                                       5/5                                       G/G   G/G
  0209                                   5/6                                       5/6                                       G/G   G/G
  0306                                   5/6                                       5/6                                       G/G   G/G
  0422                                   5/6                                       5/6                                       G/G   G/G
  0425                                   5/7                                       5/7                                       G/C   G/C
  0428                                   6/6                                       6/6                                       G/G   G/G
  0429                                   5/7                                       5/7                                       G/C   G/C
  0431                                   5/6                                       5/6                                       G/G   G/G
  0506                                   6/6                                       6/6                                       G/G   G/G
  0507                                   6/7                                       6/7                                       C/C   C/C
  0602                                   7/7                                       7/7                                       C/C   C/C
  0603                                   5/6                                       5/6                                       G/C   G/C
  0807                                   6/7                                       6/7                                       G/C   G/C
  1003                                   6/6                                       6/6                                       G/G   G/G
  1203                                   6/6                                       6/6                                       G/G   G/G
  1206                                   6/6                                       6/6                                       G/C   G/C
  1207                                   6/6                                       6/6                                       G/C   G/C
  1308                                   5/6                                       5/6                                       G/G   G/G
  1418[a](#tf2-1){ref-type="table-fn"}   5/**8**[a](#tf2-1){ref-type="table-fn"}   5/**7**[a](#tf2-1){ref-type="table-fn"}   G/C   G/C
  1603                                   6/6                                       6/6                                       G/G   G/G
  1606                                   5/6                                       5/6                                       G/G   G/G
  0036                                   7/7                                       7/7                                       C/C   C/C
  0914                                   7/8                                       7/8                                       C/C   C/C
  1214                                   6/7                                       6/7                                       C/C   C/C

Different samples were first typed by biosensor chip methodology, and then verified by capillary electrophoresis and pyrosequencing.

^a^A discrepancy reading between optical biosensor chip and capillary electrophoresis.

###### 

Allele and genotype frequencies of the *MIF* polymorphisms in Caucasian and African populations

  *MIF* polymorphism                                      Genotype, frequency no. (%)   Allele frequency (%)                                                               
  ------------------------------------------------------- ----------------------------- ---------------------- ----------- ----------- ----------- --------- ------ ------ ------
  CATT(5--8)                                              5/5                           5/6                    5/7         6/6         6/7         7/7       5      6      7
  Caucasian[a](#tf3-1){ref-type="table-fn"} (*n* = 159)   8 (5.0)                       61 (38.3)              10 (6.3)    53 (33.3)   25 (15.7)   0 (0)     27.3   60.3   11.0
  Zambia malaria (*n* = 40)                               14 (35.0)                     14 (35.0)              3 (7.5)     5 (12.5)    1 (2.5)     3 (7.5)   56.3   31.2   12.5
  African control groups (*n* = 40)                       5 (12.5)                      19 (47.5)              4 (10.0)    5 (12.5)    7 (17.5)    0 (0)     41.3   45.0   13.7
  −173 SNP G/C                                            G/G                           G/C                    C/C                                           G      C      
  Caucasian[b](#tf3-2){ref-type="table-fn"} (*n* = 88)    67 (76.1)                     21 (23.9)              0 (0)                                         88.1   11.9   
  Zambia malaria (*n* = 40)                               12 (30.0)                     12 (30.0)              16 (40.0)                                     45.0   55.0   
  African control groups (*n* = 40)                       6 (15.0)                      19 (47.5)              15 (37.5)                                     38.7   61.3   

^a^Data cited from Baugh *et al*.([@b6]).

^b^Data cited from Donn *et al*.([@b8]).

###### 

Association between parasitemia level on admission and *MIF* genotype for children evaluated at the Macha Mission Hospital in Zambia

  Parasitemia   *MIF* genotype (*n*, %)              
  ------------- ------------------------- ---------- ------
  ≤10 000       27 (84.4)                 5 (71.4)   0.04
  \>10 000      5 (15.6)                  2 (28.6)   

5 = low-expression 5-CATT *MIF* allele; X = higher expression 6-, 7- or 8-CATT *MIF* alleles.

###### 

Compilation of *MIF* allele frequencies for the CATT repeat in different population groups determined by both biochip and standard methodologies

                5/5 (%)     5/6 (%)      5/7 (%)     5/8 (%)   6/6 (%)      6/7 (%)     6/8 (%)   7/7(%)     5/5 +5/X(%)   X/X (%)      N
  ------------- ----------- ------------ ----------- --------- ------------ ----------- --------- ---------- ------------- ------------ -----
  Zambia        52 (27.6)   86 (45.7)    6 (3.2)     2 (1.1)   18 (9.6)     18 (9.6)    ---       6 (3.2)    146 (77.7)    42 (22.3)    188
  N. Africa     3 (8.8)     17 (50)      2 (5.9)     ---       4 (11.7)     5 (14.7)    ---       3 (8.8)    22 (64.7)     12 (35.3)    34
  NE Asia       18 (18)     31 (31)      13 (13)     ---       25 (25)      12 (12)     ---       1 (1)      62 (62)       38 (38.0)    100
  Caucasian     37 (6.2)    185 (30.9)   49 (8.2)    1 (0.2)   243 (40.6)   69 (11.5)   ---       13 (2.1)   272 (45.5)    325 (54.5)   597
  African Am.   31 (14.5)   73 (34.2)    22 (10.3)   1 (0.5)   45 (21.4)    35 (16.4)   2 (0.9)   4 (1.9)    127 (59.6)    86 (40.3)    213

N. Africa, North African; NE Asia, Korean; African Am., African-American; X: 6-, 7- or 8-CATT *MIF* allele.
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